Literature DB >> 10959532

Prenatal cocaine exposure impairs selective attention: evidence from serial reversal and extradimensional shift tasks.

H Garavan1, R E Morgan, C F Mactutus, D A Levitsky, R M Booze, B J Strupp.   

Abstract

This study assessed the effects of prenatal cocaine exposure on cognitive functioning, using an intravenous (IV) rodent model that closely mimics the pharmacokinetics seen in humans after smoking or IV injection and that avoids maternal stress and undernutrition. Cocaine-exposed males were significantly impaired on a 3-choice, but not 2-choice, olfactory serial reversal learning task. Both male and female cocaine-exposed rats were significantly impaired on extradimensional shift tasks that required shifting from olfactory to spatial cues; however, they showed no impairment when required to shift from spatial to olfactory cues. In-depth analyses of discrete learning phases implicated deficient selective attention as the basis of impairment in both tasks. These data provide clear evidence that prenatal cocaine exposure produces long-lasting cognitive dysfunction, but they also underscore the specificity of the impairment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959532

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  22 in total

1.  Increased "default mode" activity in adolescents prenatally exposed to cocaine.

Authors:  Zhihao Li; Priya Santhanam; Claire D Coles; Mary Ellen Lynch; Stephan Hamann; Scott Peltier; Xiaoping Hu
Journal:  Hum Brain Mapp       Date:  2011-05       Impact factor: 5.038

2.  Gender differences in prodynorphin but not proenkephalin mRNA expression in the striatum of adolescent rats exposed to prenatal cocaine.

Authors:  Annelyn Torres-Reveron; Yasmin L Hurd; Diana L Dow-Edwards
Journal:  Neurosci Lett       Date:  2007-05-05       Impact factor: 3.046

3.  Persistent cocaine-induced reversal learning deficits are associated with altered limbic cortico-striatal local field potential synchronization.

Authors:  Clinton B McCracken; Anthony A Grace
Journal:  J Neurosci       Date:  2013-10-30       Impact factor: 6.167

Review 4.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

5.  Prenatal cocaine exposure increases sensitivity to the attentional effects of the dopamine D1 agonist SKF81297.

Authors:  L E Bayer; A Brown; C F Mactutus; R M Booze; B J Strupp
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

6.  Cognitive flexibility deficits in male mice exposed to neonatal hyperoxia followed by concentrated ambient ultrafine particles.

Authors:  Keith Morris-Schaffer; Marissa Sobolewski; Kevin Welle; Katherine Conrad; Min Yee; Michael A O'Reilly; Deborah A Cory-Slechta
Journal:  Neurotoxicol Teratol       Date:  2018-10-11       Impact factor: 3.763

7.  Behavior problems among cocaine exposed children: role of physiological regulation and parenting.

Authors:  Brent Finger; Pamela Schuetze; Rina D Eiden
Journal:  Neurotoxicol Teratol       Date:  2014-01-28       Impact factor: 3.763

8.  Prenatal cocaine exposure and infant cognition.

Authors:  Lynn T Singer; Laurie J Eisengart; Sonia Minnes; Julia Noland; Arthur Jey; Courtney Lane; Meeyoung O Min
Journal:  Infant Behav Dev       Date:  2005-12

9.  Prenatal cocaine exposure alters emotional arousal regulation and its effects on working memory.

Authors:  Zhihao Li; Claire D Coles; Mary Ellen Lynch; Stephan Hamann; Scott Peltier; Stephen LaConte; Xiaoping Hu
Journal:  Neurotoxicol Teratol       Date:  2009-08-21       Impact factor: 3.763

10.  Executive functioning at ages 5 and 7 years in children with prenatal cocaine exposure.

Authors:  Fonda Davis Eyler; Tamara Duckworth Warner; Marylou Behnke; Wei Hou; Kathleen Wobie; Cynthia Wilson Garvan
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.